Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 11/20 | 0.40 |
| ▸ | CPB1 | P15086 | 6/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10655199 | 0.77 | CPB2 (0.49) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL2051187 | 0.77 | TRHR (0.31) | — | |
| SCHEMBL7209199 | 0.71 | CPB2 (0.36) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| Iodide SCHEMBL7057387 | 0.69 | CYP2C9 (0.50) | CYP2C9TSHRCYP2C19MTORHRH4 | |
| SCHEMBL4393509 | 0.69 | ALPL (0.40) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL466537 | 0.69 | QPCT (0.43) | — | |
| SCHEMBL3202060 | 0.69 | CYP2C9 (0.50) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL14416004 | 0.69 | CPB2 (0.51) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| Hydrochloric Acid SCHEMBL11092935 | 0.68 | QPCT (0.43) | TDP1 | |
| Hydrochloric Acid SCHEMBL6491461 | 0.68 | QPCT (0.43) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815863-B2 | Hydrogen bond forming fluoro ketolides for treating diseases | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Q6ZSR9, LSS, LCT | CPB2 4525/4885CPB1 3324/4885CYP2C9 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.